A non-opioid painkiller from Vertex Pharmaceuticals could become a blockbuster, but questions remain on whether it will prove safe and effective for chronic pain.

Many users later turned to heroin and now illicit fentanyl, which became the leading killer ... 2021, Eli Lilly and Pfizer abandoned a drug they jointly developed targeting arthritis pain, after ...

RALEIGH, N.C. (WTVD) -- A new non-opioid pain medication is now on the market, and those who've overcome addiction say this new way to treat pain can save lives. The brand name is Journavx ...

Ore Huiying / Bloomberg / Getty Images Pharmaceutical company Eli Lilly is expected to report fourth-quarter earnings before the bell Thursday. Analysts tracking the company see increased sales ...

Eli Lilly’s momentum stems from blockbuster GLP-1 therapies (Mounjaro, Zepbound), fuelling revenue growth, long-term margin expansion, and an ethos driving America’s health focus across ...

For the rest of her life, Andrea Magalhaes will wonder about everything her murdered 16-year-old son Gabriel will never be able to do. Never again will Gabriel explore the world, feel the wind ...

Getty Images Pharmaceutical company Eli Lilly is expected to report fourth-quarter earnings before the bell Thursday. Analysts tracking the company see increased sales and profit for Eli Lilly in ...

Mike Czapar-- Senior Vice President, Investor Relations Good morning. Thank you for joining us for Eli Lilly and Company's Q4 2024 earnings call. I'm Mike Czapar, senior vice president of investor ...

Eli Lilly (NYSE:LLY) is setting the stage for a strong 2025, with its fourth-quarter results and forward guidance reflecting solid momentum. The company's adjusted earnings per share are expected ...

Eli Lilly said it expects to release data from a late-stage trial on its next-generation weight loss drug retatrutide in 2025, a few months earlier than expected. The company expects to provide ...